Nephrotoxicity: Bacitracin in parenteral (intramuscular) therapy may cause renal failure due to tubular and glomerular necrosis. Its use should be restricted to infants with staphylococcal pneumonia and empyema when due to organisms shown to be susceptible to bacitracin. It should be used only where adequate laboratory facilities are available and when constant supervision of the patient is possible.
Renal function should be carefully determined prior to and daily during therapy. The recommended daily dose should not be exceeded and fluid intake and urinary output maintained at proper levels to avoid kidney toxicity. If renal toxicity occurs the drug should be discontinued. The concurrent use of other nephrotoxic drugs, particularly streptomycin, kanamycin, polymyxin B, polymyxin E (colistin), neomycin, and viomycin, should be avoided.
Bacitracin for Injection USP
The vial content of Bacitracin for Injection USP is sterile. The therapeutic class of the drug is antibacterial and is intended for intramuscular use.
BACiiM (Bacitracin) is indicated for the following:
In accord with the statements in the “ Warning Box ” the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Media Articles Related to Baciim (Bacitracin)
Central line infections and ventilator pneumonias decline nationwide
Source: Respiratory / Asthma News From Medical News Today [2014.09.11]
Hospitals across the country have seen sharp declines in rates of central line-associated blood stream infections (CLABSIs) and ventilator-associated pneumonias (VAPs) among critically ill neonates...
Antibiotic Lowers Death Risk for Elderly Patients With Pneumonia: Study
Source: MedicineNet azithromycin Specialty [2014.06.04]
Title: Antibiotic Lowers Death Risk for Elderly Patients With Pneumonia: Study
Category: Health News
Created: 6/3/2014 4:36:00 PM
Last Editorial Review: 6/4/2014 12:00:00 AM
Source: MedicineNet Hemolytic Uremic Syndrome Specialty [2014.01.13]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/13/2014 5:56:50 PM
Sedatives May Raise Pneumonia Risk
Source: MedicineNet temazepam Specialty [2012.12.06]
Title: Sedatives May Raise Pneumonia Risk
Category: Health News
Created: 12/5/2012 8:36:00 PM
Last Editorial Review: 12/6/2012 12:00:00 AM
Pneumonia Quiz: Test Your Medical IQ
Source: MedicineNet sulfamethoxazole Specialty [2010.12.27]
Title: Pneumonia Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 12/2/2010 6:13:00 PM
Last Editorial Review: 12/27/2010 5:42:51 PM
Published Studies Related to Baciim (Bacitracin)
Effects of feeding diets containing bacitracin methylene disalicylate to heat-stressed finishing pigs. [2011.06]
The objective of this study was to evaluate the effects of heat stress and dietary bacitracin methylene disalicylate (BMD) on growth performance, carcass characteristics, and immunological responses in finishing pigs. Four groups of 32 finishing pigs (n = 128) with initial BW between 80 to 90 kg were used...
Effects of dietary mannan oligosaccharide, bacitracin methylene disalicylate, or both on the live performance and intestinal microbiology of turkeys. [2004.07]
Hybrid male turkeys were fed to 18 wk of age in a completely randomized design with 10 replicate pens (18 birds each) per treatment to compare growth promoters. Four dietary treatments were used: negative control (CON), bacitracin methylene disalicyate (BMD) at 55 mg/kg to 6 wk and 27.5 mg/kg thereafter, mannan oligosaccharide (MOS) at 0.1% to 6 wk and 0.05% thereafter, and BMD and MOS at concentrations listed above...
The efficacy of bacitracin methylene disalicylate when fed in combination with narasin in the management of necrotic enteritis in broiler chickens. [2003.03]
The efficacy of bacitracin methylene disalicylate (BMD) in the management of necrotic enteritis (NE) when fed in combination with narasin was investigated in a floor-pen study of 2,000 broiler chickens using a Clostridium perfringens inoculum challenge model.
Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. [2001.08.15]
Patients who are colonized with enteric vancomycin-resistant Enterococcus faecium (VREF) are a major reservoir for transmission of and infection with this organism. In a randomized, controlled study to assess the effectiveness of high-dose bacitracin in the eradication of enteric VREF, 12 patients who were colonized with VREF were randomized to receive placebo (n=6) or orally administered zinc bacitracin (n=6) for 10 days...
Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. [1999.05]
We performed a randomized prospective study of 5-day treatment with topical mupirocin or bacitracin for the elimination of Staphylococcus aureus nasal colonization in healthcare workers (HCWs). Nasal cultures were obtained from 141 HCWs, 37 (26%) of whom showed S...
Clinical Trials Related to Baciim (Bacitracin)
Clinical Evaluation of Bacitracin [Completed]
The Relationship of Hemoglobin A1c and Diabetic Wound Healing [Not yet recruiting]
The purpose of this study is to investigate the relationship of hemoglobin A1c in diabetic
wound healing. Additionally, a comparison of two wound dressings, AmeriGel® (Amerx Health
Care Corp., Clearwater, FL) and Bacitracin, with and without vitamin C supplementation, will
be done to evaluate impact on time to wound closure.
Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge [Recruiting]
This study will evaluate the efficacy of a nasopore sponge dressing soaked in Bacitracin VS
a sponge soaked in Saline / and the administration of oral antibiotics.
Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds [Recruiting]
Patients will be screened at the initial visit to the burn center. If the patients are
eligible according to the inclusion/exclusion criteria, consent for the study will be
obtained. One of the investigators will identify two sites that appear to be the same depth
on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. The depth of injury will
be verified as partial thickness using laser doppler. Each site will be at least 4cm x 4cm
in size. One site will be identified for bacitracin/xeroform and one site for Polymen. All
burns will be initially debrided and cleaned according to burn unit protocol. The dressing
will then be applied. All dressings will be covered with cotton gauze and ace wraps. Laser
Doppler will be utilized to determine burn depth at both the trial and control sites. On
each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain
intensity scale. It will be noted if the wound appears infected or if antibiotics are
The study will end for each patient when the investigator determines that 95% of their burn
Nasospore Stent For Use in Enodscopic Sinus Surgery [Recruiting]
The purpose of this study is to evaluate a stenting material called Nasopore. This is a
synthetic material approved by FDA for use as a stent in postoperative sinus surgery
patients. This study will compare the Nasopore stent to other approved stenting materials.